UA57599C2 - Комплекс кобальта (ііі) с тетрадентатными основаниями шиффа c противоопухолевой активностью - Google Patents
Комплекс кобальта (ііі) с тетрадентатными основаниями шиффа c противоопухолевой активностью Download PDFInfo
- Publication number
- UA57599C2 UA57599C2 UA98127052A UA98127052A UA57599C2 UA 57599 C2 UA57599 C2 UA 57599C2 UA 98127052 A UA98127052 A UA 98127052A UA 98127052 A UA98127052 A UA 98127052A UA 57599 C2 UA57599 C2 UA 57599C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cobalt
- complexes
- complex
- tumor
- tetradentate
- Prior art date
Links
- 239000002262 Schiff base Substances 0.000 title claims abstract description 11
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical compound [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 title claims abstract 3
- -1 aliphatic schiff bases Chemical class 0.000 title abstract description 5
- 239000013522 chelant Substances 0.000 title abstract 2
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 claims abstract description 26
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 claims description 17
- 150000004753 Schiff bases Chemical class 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 230000000035 biogenic effect Effects 0.000 claims description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 29
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 abstract description 19
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract description 18
- 229910017052 cobalt Inorganic materials 0.000 abstract description 18
- 239000010941 cobalt Substances 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 10
- 201000011510 cancer Diseases 0.000 abstract description 8
- 239000000243 solution Substances 0.000 description 20
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 18
- 206010027476 Metastases Diseases 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 229960003966 nicotinamide Drugs 0.000 description 9
- 235000005152 nicotinamide Nutrition 0.000 description 9
- 239000011570 nicotinamide Substances 0.000 description 9
- 229910052697 platinum Inorganic materials 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229910052723 transition metal Inorganic materials 0.000 description 6
- 150000003624 transition metals Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 4
- 150000001868 cobalt Chemical class 0.000 description 4
- 150000004700 cobalt complex Chemical class 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical class [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000000051 modifying effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000000637 radiosensitizating effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 239000002879 Lewis base Substances 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000002001 anti-metastasis Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 150000007527 lewis bases Chemical class 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- SAXQBSJDTDGBHS-UHFFFAOYSA-N 2-azaniumylethylazanium;diacetate Chemical compound CC([O-])=O.CC([O-])=O.[NH3+]CC[NH3+] SAXQBSJDTDGBHS-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 101100023997 Caenorhabditis elegans mom-2 gene Proteins 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 229910019001 CoSi Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000922 anti-bactericidal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- LBFUKZWYPLNNJC-UHFFFAOYSA-N cobalt(ii,iii) oxide Chemical compound [Co]=O.O=[Co]O[Co]=O LBFUKZWYPLNNJC-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000000426 electronic spectroscopy Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Abstract
Изобретение относится к комплексам кобальта (ІІІ), которые могут использоваться в медицине, а именно в онкологии для лечения больных со злокачественными опухолями. Новый редокс-активный хелат кобальта с тетрадентатными основаниями Шиффа алифатического ряда имеет общую формулу (І), (I) где аксиальный лиганд L представляет собой никотинамид или изоникотинамид. .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA98127052A UA57599C2 (ru) | 1998-12-30 | 1998-12-30 | Комплекс кобальта (ііі) с тетрадентатными основаниями шиффа c противоопухолевой активностью |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA98127052A UA57599C2 (ru) | 1998-12-30 | 1998-12-30 | Комплекс кобальта (ііі) с тетрадентатными основаниями шиффа c противоопухолевой активностью |
Publications (1)
Publication Number | Publication Date |
---|---|
UA57599C2 true UA57599C2 (ru) | 2003-06-16 |
Family
ID=74285713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA98127052A UA57599C2 (ru) | 1998-12-30 | 1998-12-30 | Комплекс кобальта (ііі) с тетрадентатными основаниями шиффа c противоопухолевой активностью |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA57599C2 (ru) |
-
1998
- 1998-12-30 UA UA98127052A patent/UA57599C2/ru unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Simović et al. | Chemistry and reactivity of ruthenium (II) complexes: DNA/protein binding mode and anticancer activity are related to the complex structure | |
Antholine et al. | Inhibition of tumor cell transplantability by iron and copper complexes of 5-substituted 2-formylpyridine thiosemicarbazones | |
Reedijk | Medicinal applications of heavy-metal compound | |
Eremina et al. | Mixed-ligand copper (II) complexes with tetrazole derivatives and 2, 2′-bipyridine, 1, 10-phenanthroline: Synthesis, structure and cytotoxic activity | |
Keppler et al. | New ruthenium complexes for the treatment of cancer | |
HRP20000791A2 (en) | Platinum complex, its preparation and therapeutic application | |
Vilaplana et al. | The first isolated antineoplastic Ru (IV) complex: synthesis and structure of [Cl2 (1, 2-cyclohexanediaminotetraacetate) Ru]· 2H2 O | |
Sanghvi et al. | Antitumor properties of five-coordinate gold (III) complexes bearing substituted polypyridyl ligands | |
Hartmann et al. | Inorganic anticancer agents: Their chemistry and antitumor properties | |
Hochreuther et al. | Novel dinuclear platinum (II) complexes containing mixed nitrogen–sulfur donor ligands | |
Akkoç et al. | Protonated water-soluble N-heterocyclic carbene ruthenium (II) complexes: Synthesis, cytotoxic and DNA binding properties and molecular docking study | |
Ruggiero et al. | The photochemistry of transition metal complexes and its application in biology and medicine | |
EP0786253A1 (en) | Agent for suppressing tumour growth | |
Dallavalle et al. | Synthesis, molecular structure, solution equilibrium, and antiproliferative activity of thioxotriazoline and thioxotriazole complexes of copper (II) and palladium (II) | |
Brown et al. | Synthesis and antitumor activity of new platinum complexes | |
Bolos et al. | Synthesis, characterization, toxicity, cytogenetic and in vivo antitumor studies of 1, 1-dithiolate Cu (II) complexes with di-, tri-, tetra-amines and 1, 3-thiazoles. Structure–activity correlation | |
Ravera et al. | Synthesis, characterization, structure, molecular modeling studies and biological activity of sterically crowded Pt (II) complexes containing bis (imidazole) ligands | |
Zimbrick et al. | Studies on radiosensitization of Escherichia coli cells by cis-platinum complexes | |
Gullotti et al. | Enantiomeric cisplatin analogues: an investigation on their activity towards tumors in mice | |
Ouyang et al. | Potent saccharinate-containing palladium (II) complexes for sensitization to cancer therapy | |
UA57599C2 (ru) | Комплекс кобальта (ііі) с тетрадентатными основаниями шиффа c противоопухолевой активностью | |
Osinsky et al. | Redox-active cobalt complexes as promising antitumor agents | |
Stankovic et al. | Biological Activity of Au (III) Complexes | |
Vassilian et al. | Synthesis and antimitogenic activity of some coordination compounds of platinum (II), palladium (II) and rhodium (III) | |
Kustova et al. | Synthesis of gallium complexes of tert-butylsubstituted acyclic and cyclic compounds based on 3, 5-diamino-1, 2, 4-triazole |